FLOW

The pivotal Phase 3 trials and post-approval cardiovascular, kidney, and sleep-apnea outcome studies.

Definition

Trial of semaglutide 1 mg weekly in chronic kidney disease + type 2 diabetes (NEJM 2024). Composite kidney outcome (eGFR decline, kidney failure, renal/CV death) reduced 24%, HR 0.76.

FLOW trial: semaglutide in kidney disease →

Definition curated by Weight Loss Rankings — sourced from FDA labels and peer-reviewed PubMed literature, never AI-generated summaries.

Related terms in Major trials

STEP-1
SURMOUNT-1
SELECT
SURMOUNT-OSA
STEP-TEENS

Looking for more depth?

FLOW trial: semaglutide in kidney disease
Browse the full GLP-1 glossary (51 terms across 8 categories)
Research articles — primary-source deep dives
Tools and calculators
Compare GLP-1 telehealth providers